News & Updates

Using a 4-day, fixed-dose schedule of filgrastim as granulocyte-colony stimulating factor (G-CSF) primary prophylaxis reduces the incidence of febrile neutropenia (FN) and associated hospitalization while maintaining the doses of adjuvant docetaxel and cyclophosphamide (TC) among Chinese women with early breast cancer (BC), a retrospective cohort study in Hong Kong has shown.

Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.

Problems with pain or discomfort continue to bother young adults with juvenile idiopathic arthritis (JIA) despite their constant use of medication, a study has shown.

A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.

Treatment with fluvoxamine does not appear to improve outcomes in patients with mild-to-moderate COVID-19, with a study showing that the drug does not shorten symptom duration as compared with placebo.

START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.

Individuals with asthma may benefit from a behavioural intervention to increase their physical activity (PA), which may lead to improvements in quality of life and sleep, as well as a reduction in asthma and anxiety symptoms, suggest the results of a recent study.